CompletedInterventionalNot ApplicableUpdated Dec 1, 2021
CoolSculpting the Flanks | NCT03304925 | Trialant
Unknown statusInterventionalNot ApplicableUpdated Aug 18, 2020
CoolSculpting the Flanks
CoolSculpting the Flanks
ClinicalTrials.gov ID
NCT03304925
Lead Sponsor
Zeltiq AestheticsINDUSTRY
Overall Status
Unknown status
Study Type
Interventional
Phase
Not Applicable
Enrollment
320Estimated
Last Update Posted
Aug 18, 2020Actual
Start Date
Oct 25, 2017Actual
Primary Completion Date
Aug 2022Estimated
Completion Date
Aug 2022Estimated
Official Title
CoolSculpting the Flanks
Brief Summary
Evaluate the safety and efficacy of non-invasive subcutaneous fat layer reduction in the flanks.
Body Fat Disorder
The ZELTIQ System
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
Yes
Eligibility Criteria
Inclusion Criteria
Male or female subjects > 22 years of age and < 65 years of age.
Subject has clearly visible fat on the flanks, which in the investigator's opinion, may benefit from the treatment.
No weight change exceeding 5% of body weight in the preceding month.
Subject with body mass index (BMI) up to 30. BMI is defined as weight in pounds multiplied by 703 divided by the square of the height in inches.
Subject agrees to maintain his/her weight (i.e., within 5%) by not making any major changes in their diet or exercise routine during the course of the study.
Subject has read and signed the study written informed consent form.
Exclusion Criteria
Subject has had a surgical procedure(s) in the area of intended treatment.
Subject has had an invasive fat reduction procedure (e.g., liposuction, mesotherapy) in the area of intended treatment.
Subject has had a non-invasive fat reduction and/or body contouring procedure in the area of intended treatment within the past 12 months.
Subject needs to administer, or has a known history of subcutaneous injections into the area of intended treatment (e.g., heparin, insulin) within the past month.
Subject has a known history of cryoglobulinemia, cold urticaria, or paroxysmal cold hemoglobinuria.
Subject has a known history of Raynaud's disease, or any known condition with a response to cold exposure that limits blood flow to the skin.
Subject has a history of bleeding disorder or is taking any medication that in the investigator's opinion may increase the subject's risk of bruising.
Subject is taking or has taken diet pills or supplements within the past month.
Subject has any dermatological conditions, such as moderate to excessive skin laxity, or scars in the location of the treatment sites that may interfere with the treatment or evaluation (stretch marks is not an exclusion).
Subject has an active implanted device such as a pacemaker, defibrillator, or drug delivery system
Subject is pregnant or intending to become pregnant during the study period (in the next 8 months).
Subject is lactating or has been lactating in the past 6 months.
Subject has a history of hernia in the areas to be treated.
Subject is unable or unwilling to comply with the study requirements.
Subject is currently enrolled in a clinical study of any other unapproved investigational drug or device.
Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.
Primary Purpose
Other
Allocation
N/A
Interventional Model
Single Group Assignment
Masking
None (Open Label)
No central contacts
There are no central contacts for this study.
Innovation Research Center
Pleasanton, California 94588, United States
Laser & Skin Surgery Center of Northern California